Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00276393 · ClinicalTrials.gov registry record · Phase 4

Treatment Trial Evaluating Long Acting Insulin in Type 1 Diabetes

A Phase 4 study, sponsored by Mayo Clinic.

Completed
Registry status
Phase 4
Development phase
22
Enrollment target

NCT00276393: Completed Phase 4 study, sponsored by Mayo Clinic.

NCT00276393 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 22 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00276393, a Phase 4 study, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 4
Development phase
22 participants
Enrollment target

Study Summary

Patients with type 1 diabetes trained in multiple daily insulin injection were treated with two diffferent kinds of long acting insulin preparations. The two insulin preparations were glargine and ultralente insulin. Patients were randomized to receive one of the two insulin preparations for the first 4 months followed by the second preparation for a further four months. Short acting insulin used was the same during both periods. We found that glargine insulin was better than ultralente insulin in our study.

Interventions

  • DRUG Basal insulin

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2002-07
Est. Completion 2003-12
Phase Phase 4
Mayo Clinic

2,844 total trials

What the finished NCT00276393 record still lists

NCT00276393 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 1 intervention - of which Basal insulin is the first listed.

NCT00276393 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00276393 about?

NCT00276393 is a clinical study titled "Treatment Trial Evaluating Long Acting Insulin in Type 1 Diabetes". Patients with type 1 diabetes trained in multiple daily insulin injection were treated with two diffferent kinds of long acting insulin preparations. The two insulin preparations were glargine and ultralente insulin. Patients were randomized to receive one of the two insulin preparations for the fir...

What is the current status of trial NCT00276393?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2002-07. Estimated completion is 2003-12.

What interventions are being tested in trial NCT00276393?

The interventions under investigation include: Basal insulin (DRUG).

Who is sponsoring clinical trial NCT00276393?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00276393's enrollment target sits among peer trials

22 1731st of 2000 higher than 259 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00276393, the US trial registry maintained by the National Library of Medicine. NCT00276393 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.